Y-mAbs Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops novel antibody therapeutics and medicines for the treatment of cancer patients of all ages. Y-mAbs Therapeutics serves customers in the United States and Denmark.

Current Report (Form 8-K | Period ending 2025-09-16)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Y-mAbs Therapeutics Inc (YMAB US)

Current Report (Form 8-K | Period ending 2025-09-16)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Current Report (Form 8-K | Period ending 2025-08-08)

SC14D9C | Written communication by the subject company relating to a third party tender offer

SC14D9C | Written communication by the subject company relating to a third party tender offer

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)